Monday February 17, 2020

Alzheimer's setback makes Elan takeover bait to Biogen

Bad news for Elan’s Alzheimer’s drug is turning into good news for Biogen Idec’s takeover options.

27th July, 2012
2
Elan's Athlone plant.

Bad news for Elan’s Alzheimer’s drug is turning into good news for Biogen Idec’s takeover options.

Elan sank 15 per cent, the most since 2009, on July 24th following disappointing results for bapineuzumab, an Alzheimer’s therapy developed with Pfizer and Johnson & Johnson. The failure of that drug would leave Elan with a single major product, the multiple sclerosis treatment Tysabri that Biogen co-owns, priming the $7.1 billion company...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 1 month ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago